Financial results for Q2 ended 30 Sep,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.8 pts more than Nifty Microcap 250 and 4.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Concord Drugs Limited (BSE: 538965) reported its H1 FY26 results, with standalone net sales of Rs 2,345.63 lakhs for the six months ended September 30, 2025, down sharply from Rs 3,693.21 lakhs in the same period last year, indicating a revenue decline of roughly 36% year-on-year. Despite the top-line fall, standalone profit after tax edged up marginally to Rs 30.53 lakhs (from Rs 29.57 lakhs), with EPS of Rs 0.31 versus Rs 0.30. Consolidated results, which include subsidiary Proton Remedies Private Limited, posted net sales of Rs 2,388.25 lakhs and a PAT of Rs 31.00 lakhs. The balance sheet shows total assets growing to Rs 6,217.77 lakhs (standalone), with current borrowings of Rs 1,410.43 lakhs, and a notable increase in trade receivables from Rs 1,267.33 lakhs to Rs 1,631.27 lakhs, suggesting some working capital stretch. Operating cash flow stayed positive at Rs 335.30 lakhs, and the auditor Pundarikashyam and Associates issued a clean, unqualified limited review report with no qualifications or emphasis-of-matter items.
The sharp revenue decline is a clear negative for the stock, though flat-to-slightly-improved profitability shows some cost discipline; shareholders should watch for working capital stress from rising receivables and payables. The clean auditor opinion and positive operating cash flow provide some comfort, but the topline contraction will likely weigh on sentiment in the near term.